




# C2C12 Myoblast to Osteoblast

# Maintain at 50 – 60% Confluency by Subculturing Frequently




ATCC Number: **CRL-1772**  
Designation: **C2C12**

The cells will remain multipotent at this density but will soon need to be subcultivated.



Low Density

Scale Bar = 100µm



High Density

Scale Bar = 100µm

These cells have started to fuse into myotubes and will soon become the dominant feature of this culture.





# If too dense will spontaneously form myotubes, a differentiated stage.



Panel A: Subcultivate to maintain multipotency

Panel B: Cells have lined up and fusion into myotubes has begun.

Panel C & D: Fusion progressing as time and density increase, leading to pronounced myotubes.



# Direct differentiation into osteoblast using bone morphogenic protein 2 (BMP2).



## An overview of the provided SOP

- Set up 2 sets of 3-wells each of  $\sim 5 \times 10^3$  C2C12 cells per well in 24-well plate
  - Growth media is DMEM-HG with 10% FBS
- 1 well of each set will be an untreated control which will be allowed to grow and develop into myotubes
- Treat 1 well of each set of 3-wells with 300 ng / mL BMP2
  - Follow the SOP for BMP2 treatment protocol

# Direct differentiation into osteoblast using bone morphogenic protein 2 (BMP2).




- On day 3 or 4, change the media in the 3<sup>rd</sup> well to DMEM-HG + 2% Horse Serum
  - Optionally, you can use 0.25% FBS
  - The change in serum type or concentration will reduce the amount of growth signals while still supporting good cell proliferation
- Analyze wells on day 6 or 7 (from BMP2 treatment) for myotube formation and differentiation into osteoblasts


# Analysis of differentiation on day 6



- Compare morphology of treated to untreated controls



BMP-2 treated, Day 6



DMEM-HG+ 10% FBS, Day 6

# Direct differentiation into osteoblast using bone morphogenic protein 2 (BMP2).



- The next step in analysis is a determination of the relative activity of alkaline phosphatase (AP) in the BMP-2 treated and untreated wells
  - AP activity is significantly higher in osteoblasts than in myoblasts and this simple, quick test will show the difference by the formation of a blue-to-black precipitate in the well

# Functional assay to test for Alkaline Phosphatase Activity



- High AP activity in osteoblast, low to none in myoblast / myotubes
- Compound used is BCIP/NBT (follow protocol)

